	Stage(weeks)																		
	Route x Dosages (Drugs, Schedule)			→ MRD <1%	Induction(3-4 weeks)	Standard Risk	Consolidation(8 weeks)	Continuation(1-6 weeks)		Continuation/Reinduction(7-9 weeks)	Continuation(10-16 weeks)		Continuation(17-20 weeks)	Continua	on(21-120 weeks)				٦
				1	PO x 42 (PRE, Day15-28)	<u> </u>	PO x 56 (6-MP, Day1-56)	PO x 72 (DEX, Day1-5/Week1,4; 6-MP, Day1-42)	BMA (Day 43)	PO x 45 (DEX, Day1-8, 15-21) IV x 4 (EPI, Day 1; VCR, Day1,8.15)	PO x 64 (DEX, Day1-5/week14; 6-MP, Day1-49)	2)	PO x 58 (DEX, Day1-5/week17,20; 6-MP, Day1-28)		X, Day1-5 of week4 until week 120)				
Albanazzatia	Drugs Information Eval Name - Bouts - Evanyanav				IV x 4 (VCR, Day15, 22) IM x 3 (ASP, Day17,19,21)		IV x 4 (Pre-hydration+MTX, Day1,15, 29,43) TITx 4 (MHA, 8-12hours before MTX)	IV x 18 (EPI, VCR, MTX in Day 1,8, 15, 22, 29, 2 IM x 6 (ASP, in Day 1,8, 15, 22, 29, 26)		IM x 9 (ASP, Day3,5,7,10,12,14,17,19,21)	IV x 21 (EPI, VCR, MTX in Day 1,8, 15, 22, 29, 36,43) IM x 7(ASP, in Day 1,8, 15, 22, 29, 36,43)		IV x 3 (VCR, Day1,22; MTX,Day 8,15) IM x 7(ASP, in Day 1,8, 15, 22, 29, 36,43)	IV x 100 (VCR, Day1of every MTX, Day1-3 of ev	week until week 120; y 4 week until week 120)				
Abbrevatio	n Full Name Route Frequency			-,,		F				TITx 1(MHA, Day1)									
6-MP	6-mercaptopurine PO QD		B-precursor AL	L 1% <mrd 5%="" <="" td="" <=""><td>Induction(3-7 weeks)</td><td>──── High Risk</td><td>Consolidation(8 weeks)</td><td>Continuation(1-6 weeks)</td><td></td><td>Continuation/Reinduction-I(7-9 weeks)</td><td>Continuation(10-16 weeks)</td><td></td><td>Continuation/Reinduction-II (17-20 weeks)</td><td>Contin</td><td>ntion(21-68 weeks)</td><td>Continuation(6</td><td>9-120 weeks)</td><td>(Day</td><td>BMA nv 840)</td></mrd>	Induction(3-7 weeks)	──── High Risk	Consolidation(8 weeks)	Continuation(1-6 weeks)		Continuation/Reinduction-I(7-9 weeks)	Continuation(10-16 weeks)		Continuation/Reinduction-II (17-20 weeks)	Contin	ntion(21-68 weeks)	Continuation(6	9-120 weeks)	(Day	BMA nv 840)
ASP	L-asparaginase IM TIW		'		PO x 49 (PRE, Day15-28; 6-MP, Day22-35) IV x 9 (Cyclo, Day 22; Ara-C, Day 23-26, 30-33) IM x 6 (ASP, Day17,19,21,24,26,28)	<u> </u>	PO x 56 (6-MP, Day1-56) IV x 4 (Pre-hydration+MTX, Day1,15, 29,43) TITx 4 (MHA, 8-12hours before MTX)	PO x 72 (DEX, Day1-5/Week1,4;; 6-MP, Day1-42) IV x 18 (EPI, VCR, MTX in Day 1,8, 15, 22, 29, 26) IM x 6 (ASP, in Day 1,8, 15, 22, 29, 26)	BMA (Day 43)	IV x 5 (EPI, Day 1,8; VCR, Day1,8.15)	PO x 64 (DEX, Day1-5/week 14; 6-MP, Day1-49) IV x 21 (EPI, VCR, MTX in Day 1,8, 15, 22, 29, 36,43) IM x 7(ASP, in Day 1,8, 15, 22, 29, 36,43)	43)	PO x 52 (DEX, Day1-8, 15-21; 6-MP, Day22-28) IV x 5 (VCR, Day1,8.15)		PO x 516 (6-MP, Day1-700, DEX, Day1-5 of week4 until week 68) IV x 60 (Cyclo and Ara-C, Day 1 of week 3 per 4 weeks until week 68;		y1-5 of week4 until week 120) k until week 120;		
Ara-C	Cytarabine IV QD									IM x 9 (ASP, Day3,5,7,10,12,14,17,19,21) TIT x 1(MHA, Day1)			IM x 9(ASP, Day3,5,7,10,12,14,17,19,21) TITx 1(MHA, Day1)		r 4 weeks until week 68; per 4 weeks until week 68)	MTX, Day1-3 of every 4 v			
Cyclo	Cyclophosphmide IV QW 6 hrs, Q12H x2 day	Induction(1-2 weeks)	BMA (Day 15,50)	5% <mrd< td=""><td>Induction(3-7 weeks)</td><td>Very High Risk</td><td>Consolidation(8 weeks)</td><td>Reintensification(1 week)-HSCT option</td><td>C</td><td>Continuation(1-6 weeks)</td><td>Continuation/Reinduction-I(7-9 weeks)</td><td></td><td>Continuation(10-16 weeks) →</td><td>Continuation/Reinduction-II(17-20 w</td><td>ks)</td><td>Continuation(21-68 weeks)</td><td>Conti</td><td>uation(69-120 weeks)</td><td></td></mrd<>	Induction(3-7 weeks)	Very High Risk	Consolidation(8 weeks)	Reintensification(1 week)-HSCT option	C	Continuation(1-6 weeks)	Continuation/Reinduction-I(7-9 weeks)		Continuation(10-16 weeks) →	Continuation/Reinduction-II(17-20 w	ks)	Continuation(21-68 weeks)	Conti	uation(69-120 weeks)	
DEX	Dexamethasone PO TID	IV x 4 (VCR, Day1, 8; EPI, Day1, 8)		L	PO x 49 (PRE, Day15-28; 6-MP, Day22-35) IV x 9 (Cyclo, Day 22-23; Ara-C, Day 23-26, 30-33)	<u>'</u>	PO x 56 (6-MP, Day1-56) IV x 4 (Pre-hydration+MTX, Day1,15, 29,43)	IV x 9(Ara-C, Day1-2; VP-16,Day 3-5)		BMA (Day 1-5/Week 1, 4;; 6-MP, Day 1-42) (Day 43)	IV x 5 (EPI, Day 1,8; VCR, Day1,8.15)	· · · · · · · · · · · · · · · · · · ·	PI VCR MTX in Day 1 8 15 22 29 36 43)	PO x 52 (DEX, Day1-8, 15-21; 6-MP, Day V x 5 (VCR, Day1,8.15)	PO x 516 (6-MP, Day1-	PO x 516 (6-MP, Day1-700, DEX, Day1-5 of week4 until week 68) IV x 60 (Cyclo and Ara-C, Day 1 of week 3 per 4 weeks until week 68;		PO x 559 (6-MP, Day1-364, DEX, Day1-5 of week4 until week 120) IV x 100 (VCR, Day1of every 4 week until week 120;	
EPI	Epirubicin IV QW	IM x 6 (ASP, Day3,5,7,10,12,14) TITx 1 (MHA, No later than Day 10)			IM x 6 (ASP, Day17,19,21,24,26,28) TITx 4 (MHA, 2 times in every week)		TITx 4 (MHA, 8-12hours before MTX)		· · · · · · · · · · · · · · · · · · ·	P, in Day 1,8, 15, 22, 29, 26)			P in Day 1 8 15 22 29 36 43)	M x 9 (ASP, Day3,5,7,10,12,14,17,19,21 TITx 1(MHA, Day1)	VCR, Daylof v	week 4 per 4 weeks until week 68;	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	every 4 week until week 120,	
VP-16	Etoposide IV QD														MIX, Daylor	week 1, 2 per 4 weeks until week 68)			
MTX	Methotrexate IV QD				Induction(3-7 weeks)														
PRE	Prednisone PO TID			''	PO x 49 (PRE, Day15-28; 6-MP, Day22-35)														
VCR	Vincristine IV QW				IV x 12 (Cyclo, Day 22-23; Ara-C, Day 23-26, 30-33) IM x 6 (ASP, Day17,19,21,24,26,28)														
TIT	Methotrexate + IT QW Hydrocortisone + Ara-C(MHA)			-i															
	Ara-C(MHA)		· •	_	Induction(3-7 weeks)														
				۲۱	PO x 49 (PRE, Day15-28; 6-MP, Day22-49) IV x 18 (Cyclo, Day 22,49; Ara-C, Day 23-26, 30-33, 3	7-40 44-47)													
			<u> </u>	——→ ETP, all MRD data ——————————————————————————————————	IM x 6 (ASP, Day17,19,21,24,26,28) TITx 4 (MHA, 2 times in every week)														
					(